Trial Profile
A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Tivantinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Kyowa Hakko Kirin; Kyowa Kirin
- 22 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.